Share on StockTwits

Valeant Pharmaceuticals Intl (NYSE:VRX)‘s stock had its “buy” rating reaffirmed by stock analysts at Jefferies Group in a report issued on Friday. They currently have a $141.00 price objective on the stock, down from their previous price objective of $154.00. Jefferies Group’s target price indicates a potential upside of 19.28% from the stock’s previous close.

Valeant Pharmaceuticals Intl (NYSE:VRX) opened at 118.21 on Friday. Valeant Pharmaceuticals Intl has a 52-week low of $94.55 and a 52-week high of $153.10. The stock has a 50-day moving average of $122.3 and a 200-day moving average of $130.9. The company’s market cap is $39.632 billion.

Valeant Pharmaceuticals Intl (NYSE:VRX) last announced its earnings results on Thursday, July 31st. The company reported $1.91 earnings per share for the quarter, meeting the analysts’ consensus estimate of $1.91. The company had revenue of $1.99 billion for the quarter, compared to the consensus estimate of $1.06 billion. During the same quarter last year, the company posted $1.34 earnings per share. Valeant Pharmaceuticals Intl’s revenue was up 86.2% compared to the same quarter last year. On average, analysts predict that Valeant Pharmaceuticals Intl will post $8.59 earnings per share for the current fiscal year.

A number of other firms have also recently commented on VRX. Analysts at Deutsche Bank initiated coverage on shares of Valeant Pharmaceuticals Intl in a research note on Tuesday, July 22nd. They set a “hold” rating and a $133.00 price target on the stock. Separately, analysts at Cantor Fitzgerald raised their price target on shares of Valeant Pharmaceuticals Intl to $209.00 in a research note on Monday, June 2nd. Finally, analysts at CIBC initiated coverage on shares of Valeant Pharmaceuticals Intl in a research note on Wednesday, May 21st. They set an “outperform” rating and a $160.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $148.86.

Valeant Pharmaceuticals International, Inc, formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.